Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study

被引:35
作者
Stefanelli, Paola [1 ]
Bella, Antonino [1 ]
Fedele, Giorgio [1 ]
Pancheri, Serena [2 ]
Leone, Pasqualina [1 ]
Vacca, Paola [1 ]
Neri, Arianna [1 ]
Carannante, Anna [1 ]
Fazio, Cecilia [1 ]
Benedetti, Eleonora [1 ]
Fiore, Stefano [1 ]
Fabiani, Concetta [1 ]
Simmaco, Maurizio [3 ]
Santino, Iolanda [3 ]
Zuccali, Maria Grazia [2 ]
Bizzarri, Giancarlo [2 ]
Magnoni, Rosa [2 ]
Benetollo, Pier Paolo [2 ]
Merler, Stefano [4 ]
Brusaferro, Silvio [5 ]
Rezza, Giovanni [6 ]
Ferro, Antonio [2 ]
机构
[1] Ist Super Sanita, Dept Infect Dis, Rome, Italy
[2] APSS Azienda Prov & Serv Sanit, Trento, Italy
[3] St Andrea Univ Hosp, Hosp Direct & Clin Dept, Rome, Italy
[4] Bruno Kessler Fdn, Ctr Informat Technol, Trento, Italy
[5] Ist Super Sanita, Rome, Italy
[6] Minist Hlth, Hlth Prevent Directorate, Rome, Italy
关键词
IgG; Infection fatality rate; Population-based study; SARS-CoV-2; Seroprevalence; SEROPREVALENCE;
D O I
10.1016/j.cmi.2020.11.013
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: A seroprevalence study of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was conducted in a high-incidence area located in northeastern Italy. Methods: All citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases, were invited to participate in the study. Among 6098 participants, 6075 sera and a standardized questionnaire administered face-to-face were collected between 5 May and 15 May 2020 and examined. Symptomatic individuals and their family contacts were tested by RT-PCR. Anti-SARS-CoV-2 antibodies were detected using an Abbott SARS-CoV-2 IgG assay, which was performed on the Abbott Architect i2000SR automated analyser. Seroprevalence was calculated as the proportion of positive results among the total number tested. A multivariable logistic regression model was performed to assess the relationship between seropositive versus seronegative individuals for a set of explanatory variables. Results: A total of 1402 participants were positive for IgG antibodies against SARS-CoV-2, with a prevalence of 23.1% (1402/6075). The highest prevalence was found in the age class 40-49 years. Overall, 34.4% (2096/6098) of the participants reported at least one symptom. The ratio between reported cases identified by molecular test and those with seropositive results was 1:3, with a maximum ratio of about 1:7 in the age group <20 years and a minimum around 1:1 in those >70 years old. The infection fatality rate was 2.5% (35/1402). Among the symptoms, anosmia and ageusia were strongly associated with seropositivity. Conclusions: The estimated seroprevalence of 23% was three-fold higher than the number of cases reported in the COVID-19 Integrated Surveillance data in the study area. This may be explained in part by a relatively high number of individuals presenting mild or no illness, especially those of younger age, and people who did not seek medical care or testing, but who may contribute to virus transmission in the community. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
引用
收藏
页码:633.e1 / 633.e7
页数:7
相关论文
共 50 条
  • [21] Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak
    Lombardi, Francesca
    Ricci, Rosalba
    Belmonti, Simone
    Fabbiani, Massimiliano
    Borghetti, Alberto
    Baldin, Gianmaria
    Ciccullo, Arturo
    Tamburrini, Enrica
    Visconti, Elena
    Sanguinetti, Maurizio
    Di Giambenedetto, Simona
    DIAGNOSTICS, 2021, 11 (07)
  • [22] Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic
    Dickson, E.
    Palmateer, N. E.
    Murray, J.
    Robertson, C.
    Waugh, C.
    Wallace, L. A.
    Mathie, L.
    Heatlie, K.
    Mavin, S.
    Gousias, P.
    Von Wissman, B.
    Goldberg, D. J.
    McAuley, A.
    PUBLIC HEALTH, 2021, 190 : 132 - 134
  • [23] SARS-CoV-2 IgG seroprevalence in personnel of the extraclinical fight against the COVID-19 pandemic
    Brune, Bastian
    Korth, Johannes
    Fessmann, Kai
    Stappert, Daniel
    Nohl, Andre
    Lembeck, Thomas
    Standl, Fabian
    Stang, Andreas
    Dittmer, Ulf
    Witzke, Oliver
    Herrmann, Anke
    Dudda, Marcel
    NOTFALL & RETTUNGSMEDIZIN, 2023, 26 (08): : 593 - 601
  • [24] INDICATORS OF ANTIBODIES IgM AND IgG TO SARS-COV-2 IN RESIDENTS OF YAKUTSK AFTER RECOVERY FROM COVID-19
    Efremova, S. D.
    Okhlopkova, E. D.
    Grigorieva, A. A.
    Olesova, L. D.
    Romanova, A. N.
    YAKUT MEDICAL JOURNAL, 2021, (04): : 85 - 88
  • [25] Sero-Prevalence and Sero-Incidence of Antibodies to SARS-CoV-2 in Health Care Workers in Israel, Prior to Mass COVID-19 Vaccination
    Muhsen, Khitam
    Schwaber, Mitchell J.
    Bishara, Jihad
    Kassem, Eias
    Atamna, Alaa
    Na'amnih, Wasef
    Goren, Sophy
    Bialik, Anya
    Mohsen, Jameel
    Zaide, Yona
    Hazan, Nimrod
    Ariel-Cohen, Ortal
    Cohen, Regev
    Shitrit, Pnina
    Marchaim, Dror
    Benenson, Shmuel
    Ben-David, Debby
    Rubinovitch, Bina
    Gotessman, Tamar
    Nutman, Amir
    Wiener-Well, Yonit
    Maor, Yasmin
    Carmeli, Yehuda
    Cohen, Dani
    FRONTIERS IN MEDICINE, 2021, 8
  • [26] Asymptomatic SARS-COV-2 carriage and sero-positivity in high risk contacts of COVID-19 cases'
    Das, Ayan Kumar
    Chandra, Kailash
    Dudeja, Mridu
    Aalam, Mohd Khursheed
    INDIAN JOURNAL OF MEDICAL MICROBIOLOGY, 2022, 40 (02) : 279 - 284
  • [27] Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19
    Gregory, David J.
    Vannier, Augustin
    Duey, Akiro H.
    Roady, Tyler J.
    Dzeng, Richard K.
    Pavlovic, Maia N.
    Chapin, Michael H.
    Mukherjee, Sonia
    Wilmot, Hannah
    Chronos, Nic
    Charles, Richelle C.
    Ryan, Edward T.
    LaRocque, Regina C.
    Miller, Tyler E.
    Garcia-Beltran, Wilfredo F.
    Thierauf, Julia C.
    Iafrate, A. John
    Mullenbrock, Steven
    Stump, Mark D.
    Wetzel, Randall K.
    Polakiewicz, Roberto D.
    Naranbhai, Vivek
    Poznansky, Mark C.
    VIRULENCE, 2022, 13 (01) : 890 - 902
  • [28] Prevalence of SARS-CoV-2-specific antibodies in a sample of the Lithuanian population-based study in Spring 2023
    Simanavic, Martynas
    Kucinskaite-Kodze, Indre
    Kaseliene, Snieguole
    Sauliune, Skirmante
    Gudas, Dainius
    Jancoriene, Ligita
    Jasinskiene, Ruta
    Vitkauskiene, Astra
    Zutautiene, Rasa
    Zvirbliene, Aurelija
    Stankunas, Mindaugas
    HELIYON, 2024, 10 (08)
  • [29] Dynamic changes of SARS-CoV-2 specific IgM and IgG among population vaccinated with COVID-19 vaccine
    Chen, Fengling
    Zhong, Yi
    Li, Jiazhao
    Luo, Jianrong
    EPIDEMIOLOGY AND INFECTION, 2022, 150
  • [30] Seroprevalence of SARS-CoV-2 (COVID-19) antibodies in tertiary care hospital of Karachi, Pakistan
    Fatima, Ambreen
    Fasih, Fatima
    Baig, Samina
    Khan, Fouzia Zeeshan
    Naseem, Saima
    Qureshi, Muhammad Asif
    RAWAL MEDICAL JOURNAL, 2023, 48 (01): : 70 - 73